Prdx2 suppresses the erythroid differentiation by modulating the ROS-JNK1 signaling axis.
Erythroleukemia is a rare but aggressive subtype of acute myeloid leukemia with a poor prognosis and limited therapeutic options. Impaired erythroid differentiation is a hallmark of this disease, yet the underlying molecular mechanisms remain incompletely understood. Peroxiredoxin 2 (PRDX2), a key antioxidant enzyme in...